Frontiers in Psychiatry最新文献

{"title":"Novel hematologic ratios and systemic inflammation index in ADHD: effects of methylphenidate treatment.","authors":"Meryem Kaşak, Hande Günal Okumuş, Yusuf Selman Çelik, Fatma Zehra Kırşan, Yusuf Öztürk, Ayşegül Efe","doi":"10.3389/fpsyt.2025.1621767","DOIUrl":"https://doi.org/10.3389/fpsyt.2025.1621767","url":null,"abstract":"<p><strong>Background: </strong>Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, and recent research suggests systemic inflammation contributes to its pathophysiology. This study aimed to evaluate novel inflammatory markers-neutrophil-to-HDL ratio (NHR), lymphocyte-to-HDL ratio (LHR), monocyte-to-HDL ratio (MHR), platelet-to-HDL ratio (PHR), and systemic immune-inflammation index (SII)-in children with ADHD compared to healthy controls. Additionally, it assessed changes in these markers after 12 weeks of long-acting methylphenidate treatment and potential differences among ADHD subtypes.</p><p><strong>Methods: </strong>This prospective study included 114 newly diagnosed, treatment-naive ADHD patients (aged 6-12) and 52 matched controls. Blood samples were obtained at baseline and after 12 weeks of treatment. Inflammatory markers were calculated from complete blood count and HDL levels. ADHD symptom severity was assessed using the Conners Parent Rating Scale-Revised: Short Form (CPRS-R:S), and anxiety and depression were measured with the Revised Child Anxiety and Depression Scale (RCADS).</p><p><strong>Results: </strong>ADHD patients showed significantly elevated baseline levels of NHR, LHR, MHR, PHR, and SII compared to controls (Cohen's d range = 0.17-0.69). NHR independently predicted ADHD. Post-treatment, all inflammatory markers significantly decreased, suggesting a potential anti-inflammatory effect of methylphenidate (Cohen's d range = 0.17-0.91). Post-treatment LHR was higher in the combined ADHD subtype.</p><p><strong>Conclusions: </strong>This study underscores inflammation's role in ADHD and suggests these markers may reflect systemic inflammation in ADHD, but their clinical utility requires further investigation.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1621767"},"PeriodicalIF":3.2,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight bias in mental health settings: a scoping review.","authors":"Samantha R Philip, Erin C Standen, Jordan Schueler, Sherecce A Fields, Sean M Phelan","doi":"10.3389/fpsyt.2025.1596625","DOIUrl":"https://doi.org/10.3389/fpsyt.2025.1596625","url":null,"abstract":"<p><strong>Introduction: </strong>Weight bias is a pervasive form of prejudice, most deeply and directly harming individuals in larger bodies. Although the mental health field strives to promote the delivery of equitable, culturally sensitive care, the prevalence and nature of weight bias in therapeutic contexts are not well understood. This scoping review examines how weight bias manifests within mental health settings and its impacts on client care and outcomes, exploring the issue from both client and provider lenses.</p><p><strong>Methods: </strong>A total of 43 studies meeting search criteria were identified from a systematic search process.</p><p><strong>Results: </strong>Findings indicate that mental health professionals (MHPs) hold negative stereotypes toward larger-bodied individuals. Although MHPs were less likely to report having negative attitudes, they reported a high prevalence of weight bias in their colleagues. Studies using experimental designs demonstrated that providers' clinical judgment and decision-making were impacted by client body size, generally showing that higher-weight clients were perceived to have lower global functioning, greater pathology, and more negative attributes than lower-weight clients. When the client was described with restrictive eating disorder symptomatology, however, MHPs rated higher-weight clients as less severe and recommended less intensive treatment compared to lower-weight clients. Qualitative studies from client samples revealed experiences of weight stigma during treatment, including MHPs' expressions of implicit and explicit weight bias, assumptions and misattributions based on the clients' weight, unsolicited (direct or subtle) weight loss advice, and differential treatment based on size. Experiences of weight bias were harmful to the client's therapeutic progress and undermined their trust in their provider and the mental health system at large.</p><p><strong>Discussion: </strong>The body of evidence suggests that weight bias is a serious and significant barrier to the provision of equitable mental health treatment and mental health equity.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1596625"},"PeriodicalIF":3.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clomipramine potentially induced fatal torsades de pointes in a patient with acute decompensated heart failure: a case report.","authors":"Rong-Hua Wang, Yu-Liang Lu, Jia-Hui Lu","doi":"10.3389/fpsyt.2025.1595211","DOIUrl":"https://doi.org/10.3389/fpsyt.2025.1595211","url":null,"abstract":"<p><strong>Background: </strong>While clomipramine is generally considered lower risk for QT prolongation among tricyclic antidepressants, its potential to induce torsades de pointes (TdP) remains poorly characterized, particularly in patients with multiple risk factors.</p><p><strong>Case presentation: </strong>A 78-year-old male with a history of hypertension, atrial fibrillation, and post-stroke depression presented to the emergency department with a one-week history of chest distress. Initial evaluation revealed atrial fibrillation with a prolonged QTc interval of 550 ms on electrocardiogram (ECG) monitoring, and elevated B-type natriuretic peptide (1130 pg/mL). The patient was admitted for acute decompensated heart failure and treated with torasemide intravenously while continuing clomipramine (25 mg daily) for depression. Within 24 hours, he experienced multiple episodes of torsades de pointes (TdP), coinciding with hypokalemia (serum potassium: 3.21 mmol/L). Despite corrective measures, including potassium and magnesium supplementation, the patient developed ventricular fibrillation and cardiac arrest, leading to death.</p><p><strong>Conclusion: </strong>This case highlights the potential risk of clomipramine-induced QT prolongation and TdP, particularly in patients with acute heart failure and electrolyte imbalances, underscoring the need for careful risk assessment and monitoring in such populations.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1595211"},"PeriodicalIF":3.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials.","authors":"Chen Xu, Yang Zhao, Xueqin Yang, Juan Zheng, Qian Tang","doi":"10.3389/fpsyt.2025.1599038","DOIUrl":"https://doi.org/10.3389/fpsyt.2025.1599038","url":null,"abstract":"<p><strong>Objective: </strong>To understand the current status of research and development (R&D) of psychotropic drugs.</p><p><strong>Methods: </strong>Retrieved psychotropic drugs clinical trials (PDCTs) registered in China from 2019 to 2024 using the platform of <i>chinadrugtrials.org.cn</i>, and systematically analyzed the data.</p><p><strong>Results: </strong>Included four perspectives: 1) for general information, we screened 1377 PDCTs, with phase bioequivalency (BE) accounting for the majority (78.5%), covering 411 pharmaceutical companies and 212 leading institutions, and the start-up time in 2024 was significantly shortened (<i>P</i> < 0.05); 2) for indications, 11 indications were involved, with the highest number of PDCTs for depression (30.9%); 3) for drugs, 222 drugs were involved, of which 52 were innovative drugs (33 with disclosed targets), and 13 were improved new drugs with six administration routes; 4) for trial design, four exploratory designs were retrieved, including population pharmacokinetics (9), pharmacogenomics (12), biomarker detection (3), and drug combination (3).</p><p><strong>Conclusions: </strong>In recent years, clinical trials of psychotropic drugs in China have been developing. Innovative targets discovery, dosage forms/drug delivery systems optimization, and exploratory designs have the potential to break the current treatment dilemma. This study introduced the hotspots and potential development directions of psychotropic drugs R&D in China from the above aspects, providing new ideas for psychiatric treatment, drug development, and clinical trial methods.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1599038"},"PeriodicalIF":3.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mediating role of body roundness index in the association between dietary inflammatory index and depression: evidence from the US National Health and Nutrition Examination Survey 2007-2023.","authors":"Weige Duan, Jian Ma, Shanglan Qu, Jing Zhang, Min Li, Lizhu Jiang","doi":"10.3389/fpsyt.2025.1605449","DOIUrl":"https://doi.org/10.3389/fpsyt.2025.1605449","url":null,"abstract":"<p><strong>Objective: </strong>Dietary inflammatory index (DII) and body roundness index (BRI) have been reported to be independently associated with an increased risk of depression. The purpose of this study was to examine the mediating role of BRI in the relationship between DII and depression.</p><p><strong>Methods: </strong>A total of 32,210 adults were recruited from the National Health and Nutrition Examination Survey (NHANES; 2007-2023). Depression was assessed with Patient Health Questionnaire-9 (PHQ-9), DII and BRI were calculated for each participant. Weighted multivariate logistic regressions, Spearman's correlation, and mediation analysis were performed.</p><p><strong>Results: </strong>A higher DII was significantly associated with an increased risk of depression (OR=1.68, 95% CI: 1.32-2.13, p<0.001). Compared with the lowest quintile (Q1) of BRI, individuals in the highest quintile (Q5) showed a significantly higher risk of depression (OR=1.90, 95% CI: 1.08-3.36, p=0.027). Furthermore, both DII (r=0.071) and BRI (r=0.112) were positively correlated with depressive symptoms, and DII was also positively correlated with BRI (r=0.118), all p<0.001. Of note, BRI partially mediated the relationship between DII and depression (indirect effect 0.002, 95% CI: 0.001-0.003), accounting for 10.7% of the total effect. The mediating effect of BRI was verified in both male and female population.</p><p><strong>Conclusions: </strong>This study firstly identified a mediating role of BRI in the association between DII and depressive symptoms, suggesting that visceral obesity may be an important pathway through which dietary inflammation affects depression. Our findings may provide evidence-based insights to guide targeted interventions to prevent depression at the population level.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1605449"},"PeriodicalIF":3.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Suicidality and self-injury behaviours across the lifespan in mental and substance use disorders.","authors":"Ruta Karaliuniene, Ramdas Ransing, Laura Orsolini","doi":"10.3389/fpsyt.2025.1639200","DOIUrl":"https://doi.org/10.3389/fpsyt.2025.1639200","url":null,"abstract":"","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1639200"},"PeriodicalIF":3.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering transcriptomic signatures in schizophrenia, bipolar disorder, and major depressive disorder.","authors":"Priyanka, Rajesh Kumar, Vinod Kumar, Ashwani Kumar, Sandeep Singh Rana","doi":"10.3389/fpsyt.2025.1574458","DOIUrl":"10.3389/fpsyt.2025.1574458","url":null,"abstract":"<p><p>Schizophrenia (SCZ), Bipolar Disorder (BD), and Major Depressive Disorder (MDD) are severe psychiatric conditions that share overlapping clinical symptoms, yet they differ in their underlying molecular mechanisms. Despite extensive research, the biological foundations of these disorders remain incompletely understood. In this study, we performed a large-scale transcriptomic analysis by integrating 557 publicly available RNA-seq datasets from post-mortem brain tissues, spanning multiple regions, to better understand the shared and distinct molecular features of these disorders. Using systematic bioinformatic approaches, we identified differentially expressed genes (DEGs) and investigated associated biological pathways, regulatory transcription factors, and drug-gene interactions. Our analysis revealed notable overlap in gene expression profiles, particularly between SCZ and BD, suggesting common molecular pathways underlying these disorders. At the same time, each disorder also demonstrated unique transcriptional patterns, supporting the existence of disorder-specific mechanisms. Brain region-specific analyses further highlighted spatial heterogeneity in gene expression, with significant differences observed in regions such as the hippocampus and dorsolateral prefrontal cortex (DLPFC). The transcription factor enrichment analysis revealed distinct regulatory programs driving each disorder: MDD pathology appears regulated by ASCL3, MYOG, HNF1B, RUNX3, FOXA1 and STAT4; BD exhibited predominant control by immune-regulatory factors including FOSL1, FOSL2, PLSCR1, RELB, BATF3, IRF and NFKB1; while SCZ demonstrated unique regulation through ATF5, CREB3L3, SNAI1, NFIL3, CEBPB, RELB and IRF transcription factors. Moreover, our drug-gene interaction analysis uncovered promising therapeutic targets, with several differentially expressed genes showing potential for drug repurposing, particularly in relation to antipsychotics and immunomodulatory agents. Our comprehensive transcriptomic analysis reveals both shared molecular mechanisms and distinct immune signatures across schizophrenia, bipolar disorder, and major depressive disorder, advancing our understanding of psychiatric pathophysiology while highlighting the heterogeneous nature of these conditions. These findings establish a critical foundation for developing targeted, patient-specific therapeutic interventions that address the underlying biological complexity of major psychiatric disorders.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1574458"},"PeriodicalIF":3.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of acupuncture on menopausal depressive disorder and serum hormone levels: a systematic review and meta-analysis.","authors":"Shunxia He, Zhijie Wang, Shiqiu Dong, Yuzi Diao, Hongwei Qiao, Xiaoguang Lin, Xiao Gao","doi":"10.3389/fpsyt.2025.1591389","DOIUrl":"10.3389/fpsyt.2025.1591389","url":null,"abstract":"<p><strong>Background: </strong>Menopause, marked by ovarian decline and hormonal shifts, increases vulnerability to depressive disorders, with menopausal depressive disorder (MDD) affecting 33-36% of women via psychosocial-biological interactions. Acupuncture shows promise in improving MDD through neuroendocrine regulation but lacks robust evidence, with unclear links to reproductive hormone modulation; this study evaluates its efficacy and safety.</p><p><strong>Methods: </strong>A comprehensive database search was conducted using PubMed, Embase, the Cochrane Library, Web of Science, EBSCO, Scopus, Cnki, Wan Fang and VIP Database to identify randomized controlled trials (RCTs) investigating the impact of acupuncture on menopausal depressive disorder. RCTs published until April 21, 2025, that met our predetermined inclusion and exclusion criteria were included. Data extraction, literature review, and assessment of the methodological quality of the trials were performed. The meta-analysis was conducted using Review Manager (RevMan) 5.3 software.</p><p><strong>Results: </strong>Our findings demonstrate that acupuncture significantly outperforms control interventions in improving clinical effectiveness rates (OR=2.70, 95%CI[1.63,4.48], P=0.0001) and reducing depressive symptoms, as evidenced by HAMD-17 (SMD=-0.28, P<0.0001) and HAMD-24 scores (post-sensitivity SMD=-0.39, P=0.03). Notably, acupuncture also enhanced quality of life (MENQOL: SMD=-0.25, P=0.003), though its effects on sex hormones (FSH, LH, E2) remained nonsignificant (P>0.05). Safety profiles were comparable between groups (OR=0.16, P=0.05), yet sensitivity analysis revealed reduced adverse events in the acupuncture group after excluding outlier studies (OR=0.49, P=0.03). In conclusion, the intervention of acupuncture is beneficial for MDD.</p><p><strong>Conclusion: </strong>This systematic review demonstrates that acupuncture serves as an effective and safe non-pharmacological intervention for alleviating menopausal depressive symptoms and improving quality of life. While acupuncture did not significantly modulate sex hormone levels, its therapeutic benefits are likely mediated through non-hormonal mechanisms, such as neurotransmitter regulation and neuroendocrine network modulation.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier CRD420251037010.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1591389"},"PeriodicalIF":3.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The bridge between anxiety and insomnia symptoms among Chinese adults before and after SARS-CoV-2 vaccination: a network analysis.","authors":"Yan Liu, Shangyu Luo, Chao Jiang, Jing Guo, Minhui Dai, Li Feng, Mingxia Li, Jun Wen, Xiaobo Zhang","doi":"10.3389/fpsyt.2025.1604309","DOIUrl":"10.3389/fpsyt.2025.1604309","url":null,"abstract":"<p><strong>Background: </strong>To explore the underlying mechanism and changes of anxiety and insomnia before and after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, we conducted an online cross-sectional survey.</p><p><strong>Methods: </strong>This is a cross-sectional study conducted in two phases: the first phase was from May to June 2020 (before vaccination) and the second phase was from June to August 2021 (after vaccination). In total, 2245 participants were enrolled before vaccination, and 7207 participants were enrolled after vaccination. Anxiety was measured using the Generalized Anxiety Disorder-7(GAD-7) Scale and insomnia using the Athens Insomnia Scale-8(AIS-8) Scale. Network analysis models were applied to examine the correlation between anxiety and insomnia. Furthermore, a network comparison test was performed to compare network characteristics before and after vaccination.</p><p><strong>Results: </strong>Our work showed that participants' anxiety and insomnia scores were lower after vaccination than before vaccination. Sense of well-being during the day (AIS6) in AIS remained high both before and after vaccination. The central intensity of premature wakefulness (AIS3), feeling afraid, and functioning (physical and mental) during the day (AIS7) decreased after vaccination, and the mediation between sense of well-being during the day (AIS6) and sleeping during the day (AIS8) increased significantly.</p><p><strong>Limitations: </strong>The study was a cross-sectional survey. The numbers of participants differed much in the two groups.</p><p><strong>Conclusions: </strong>The proportion of participants experiencing anxiety and insomnia decreased significantly after SARS-CoV-2 vaccination. Network analysis identified psychosis-related symptoms as key links between anxiety and insomnia. These findings suggest that targeted interventions focusing on daytime emotional regulation could improve mental health outcomes, guiding healthcare practices during public health crises.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1604309"},"PeriodicalIF":3.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Art therapy with an African American female combat veteran experiencing effects of mild traumatic brain injury and post-traumatic stress.","authors":"Gioia Chilton, Jennifer Marie DeLucia, Myissha Tompkins","doi":"10.3389/fpsyt.2025.1512565","DOIUrl":"10.3389/fpsyt.2025.1512565","url":null,"abstract":"<p><p>This retrospective case study explored the use of art therapy (AT) with an AfricanAmerican female combat veteran experiencing the effects of mild traumatic brain injury (mTBI) and co-occurring post-traumatic stress disorder (PTSD). The study aimed to understand how culturally informed military AT functions in the treatment of a female service member with mTBI and PTSD. Qualitative data were collected from artwork, case notes, and the therapist's clinical reflections. Quantitative data were collected using the Emotion Regulation Strategies for Artistic Creative Activities Scale (ERS-ACA). Thematic analysis and ERS-ACA results revealed several themes. The results illustrated that art therapy supported the client to express her needs, strengths, and treatment progress; it facilitated emotional expression; supported the expression of cultural identity; and provided a method for communicating her needs to others outside of art therapy sessions. This case study underscores the potential for utilizing standardized art therapy treatment methods to benefit military-connected individuals with similar conditions.</p>","PeriodicalId":12605,"journal":{"name":"Frontiers in Psychiatry","volume":"16 ","pages":"1512565"},"PeriodicalIF":3.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}